J&J intensifies vaccine endeavour with Bavarian Nordic
Johnson & Johnson has entered a new deal with Danish biotech Bavarian Nordic worth up to US$879m to develop vaccine regimens against hepatitis B and HIV.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1224 entries already.
Entries by Thomas Gabrielczyk
GSK cancels 30 preclinical and clinical programmes
/in News/by Thomas GabrielczykUKs biggest pharma firm announced it will save an additional £1bn each year by 2020. 80% of the pharmaceutical R&D pipeline expenses will be directed towards two current (Respiratory and […]
Ablynx adds Sanofi to its list of pharma partners
/in News/by Thomas GabrielczykBelgian nanobody-developer Ablynx NV now also works together with French pharma company Sanofi. The deal is potentially worth 2.4bn but comes with an upfront payment of just 23m. The partners […]
Seventure debuts in Japan with microbiome investment
/in News/by Thomas GabrielczykVenture capitalist Seventure Partners announced that it has participated in a US$13m financing of Japanese biotech company Anaeropharma Science. The investment is made from Seventures Health for Life Capital investment […]